134 results on '"Haaland B"'
Search Results
2. Synovial fluid pro-inflammatory profile differs according to the characteristics of knee pain
- Author
-
Leung, Y.Y., Huebner, J.L., Haaland, B., Wong, S.B.S., and Kraus, V.B.
- Published
- 2017
- Full Text
- View/download PDF
3. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
- Author
-
Inker, L.A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G.B., Badve, S.V., Caravaca-Fontán, F., Vecchio, L. Del, Floege, J., Goicoechea, M., Haaland, B., Herrington, W.G., Imai, E., Jafar, T.H., Lewis, J.B., Li, P.K.T., Maes, B.D., Neuen, B.L., Perrone, R.D., Remuzzi, G., Schena, F.P., Wanner, C., Wetzels, J.F.M., Woodward, M., Heerspink, H.J.L., Inker, L.A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G.B., Badve, S.V., Caravaca-Fontán, F., Vecchio, L. Del, Floege, J., Goicoechea, M., Haaland, B., Herrington, W.G., Imai, E., Jafar, T.H., Lewis, J.B., Li, P.K.T., Maes, B.D., Neuen, B.L., Perrone, R.D., Remuzzi, G., Schena, F.P., Wanner, C., Wetzels, J.F.M., Woodward, M., and Heerspink, H.J.L.
- Abstract
01 juli 2023, Contains fulltext : 294975.pdf (Publisher’s version ) (Closed access), Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. Analyses across a diverse spectrum of interventions and populations is required for acceptance of GFR decline as an endpoint. In an analysis of individual participant data, for each of 66 studies (total of 186,312 participants), we estimated treatment effects on the total GFR slope, computed from baseline to 3 years, and chronic slope, starting at 3 months after randomization, and on the clinical endpoint (doubling of serum creatinine, GFR < 15 ml min(-1) per 1.73 m(2) or kidney failure with replacement therapy). We used a Bayesian mixed-effects meta-regression model to relate treatment effects on GFR slope with those on the clinical endpoint across all studies and by disease groups (diabetes, glomerular diseases, CKD or cardiovascular diseases). Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median coefficient of determination (R(2)) = 0.97 (95% Bayesian credible interval (BCI) 0.82-1.00)) and moderately associated with those on chronic slope (R(2) = 0.55 (95% BCI 0.25-0.77)). There was no evidence of heterogeneity across disease. Our results support the use of total slope as a primary endpoint for clinical trials of CKD progression.
- Published
- 2023
4. 322P Genomic landscape of early-onset sporadic colorectal cancer
- Author
-
Holowatyj, A.N., primary, Hardikar, S., additional, Nix, D., additional, Haaland, B., additional, Larson, M., additional, Siegel, E.M., additional, Carpten, J., additional, Hampel, H., additional, Kennedy, T., additional, Lieu, C., additional, Reilley, M.J., additional, Pearlman, R., additional, Lewis, M., additional, Churchman, M., additional, Colman, H., additional, and Ulrich, C., additional
- Published
- 2022
- Full Text
- View/download PDF
5. P63.11 Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy
- Author
-
Kerrigan, K., primary, Sinnott, J., additional, Haaland, B., additional, Puri, S., additional, Akerley, W., additional, and Patel, S., additional
- Published
- 2021
- Full Text
- View/download PDF
6. P89.05 Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis
- Author
-
Kerrigan, K., primary, Puri, S., additional, Sinnott, J., additional, Haaland, B., additional, Akerley, W., additional, and Patel, S., additional
- Published
- 2021
- Full Text
- View/download PDF
7. FP05.01 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy
- Author
-
Kerrigan, K., primary, Chipman, J., additional, Jo, Y.J., additional, Haaland, B., additional, Johnson, E., additional, Puri, S., additional, Varghese, T., additional, Akerley, W., additional, and Patel, S., additional
- Published
- 2021
- Full Text
- View/download PDF
8. OA09.05 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy
- Author
-
Kerrigan, K., primary, Chipman, J., additional, Jo, Y.J., additional, Haaland, B., additional, Johnson, E., additional, Puri, S., additional, Varghese, T., additional, Akerley, W., additional, and Patel, S., additional
- Published
- 2021
- Full Text
- View/download PDF
9. INCORPORATING HEART RATE VARIABILITY AND VITAL SIGNS IN THE PREDICTION OF ACUTE CARDIAC COMPLICATIONS IN EMERGENCY DEPARTMENT PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME: 112
- Author
-
Ong, M. E., Goh, J. Y., Fook-Chong, S., Haaland, B., and Lin, Z.
- Published
- 2012
10. 462P Treatment trends and clinical outcomes of left sided, RAS/RAF wild type metastatic colorectal cancer in the United States
- Author
-
Nevala-plagemann, C.D., primary, Paapas, L., additional, Haaland, B., additional, and Garrido-Laguna, I., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Low‐value Prostate Cancer Screening: Decision Fatigue in Outpatient Providers’ PSA Testing Practices
- Author
-
Hunt, T.C., primary, Ambrose, J.P., additional, Haaland, B., additional, Hanson, H.A., additional, and O'Neil, B.B., additional
- Published
- 2020
- Full Text
- View/download PDF
12. MA14.09 Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer
- Author
-
Kerrigan, K., primary, Haaland, B., additional, Adamson, B., additional, Patel, S., additional, and Akerley, W., additional
- Published
- 2019
- Full Text
- View/download PDF
13. P1.04-67 First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) – A Network Meta-Analysis by PD-L1
- Author
-
San Tan, P., primary, Aguiar Junior, P. Nazareth, additional, Husnain, M., additional, Haaland, B., additional, and Lopes, G., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
- Author
-
Magalhaes, M., primary, Aguiar, P., additional, Haaland, B., additional, del Giglio, A., additional, and Lopes, G., additional
- Published
- 2019
- Full Text
- View/download PDF
15. P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers
- Author
-
Kerrigan, K., primary, Haaland, B., additional, Adamson, B., additional, Patel, S., additional, and Akerley, W., additional
- Published
- 2019
- Full Text
- View/download PDF
16. P3.01-13 Prognosis of Non-driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)
- Author
-
Chalmers, A., primary, Haaland, B., additional, Patel, S., additional, Moynahan, K., additional, Cannon, L., additional, and Akerley, W., additional
- Published
- 2018
- Full Text
- View/download PDF
17. P2.07-055 Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer – a Network Meta-Analysis
- Author
-
Tan, P., primary, Aguiar, P., additional, Haaland, B., additional, and Lopes, G., additional
- Published
- 2017
- Full Text
- View/download PDF
18. P2.07-054 Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
- Author
-
Georgieva, M., primary, Aguiar, P., additional, Lima, J.P., additional, Haaland, B., additional, and Lopes, G., additional
- Published
- 2017
- Full Text
- View/download PDF
19. Techniques of Payment to Hospitals
- Author
-
HAALAND, B. H. and MacKAY, CYRIL M.
- Published
- 1958
20. Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (colkoa): a randomized controlled trial
- Author
-
Leung, Y.Y., primary, Thumboo, J., additional, Wong, S.B., additional, Haaland, B., additional, Huebner, J.L., additional, Chowbay, B., additional, Chakraborty, B., additional, Tan, M., additional, and Kraus, V.B., additional
- Published
- 2017
- Full Text
- View/download PDF
21. 253P - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
- Author
-
Magalhaes, M., Aguiar, P., Haaland, B., del Giglio, A., and Lopes, G.
- Published
- 2019
- Full Text
- View/download PDF
22. Association between radiographic severity and pain in knee osteoarthritis
- Author
-
Leung, Y.Y., primary, Wong, B., additional, Haaland, B., additional, and Kraus, V.B., additional
- Published
- 2016
- Full Text
- View/download PDF
23. 444P Overall survival (OS) by EGFR mutation status and subtypes (Deletion 19/L858R) for first-line therapies with maintenance regimens in advanced non-small-cell lung cancer (NSCLC): a Bayesian multiple treatment comparison (MTC) meta-analysis
- Author
-
Tan, P.S., primary, Lopes, G., additional, Aacharyya, S., additional, Bilger, M., additional, and Haaland, B., additional
- Published
- 2015
- Full Text
- View/download PDF
24. Lamina Cribrosa Visibility Using Optical Coherence Tomography: Comparison of Devices and Effects of Image Enhancement Techniques
- Author
-
Girard, M. J. A., primary, Tun, T. A., additional, Husain, R., additional, Acharyya, S., additional, Haaland, B. A., additional, Wei, X., additional, Mari, J. M., additional, Perera, S. A., additional, Baskaran, M., additional, Aung, T., additional, and Strouthidis, N. G., additional
- Published
- 2015
- Full Text
- View/download PDF
25. Tumor Vascular Heterogeneity As a Biomarker of Response to Anti-Angiogenic Treatment in Patients with Nasopharyngeal Carcinoma
- Author
-
Teo, Q.Q., primary, Haaland, B., additional, Thng, C.H., additional, Lim, W.T., additional, Koh, T.S., additional, and Ng, Q., additional
- Published
- 2014
- Full Text
- View/download PDF
26. Sudoku-based space-filling designs
- Author
-
Xu, X., primary, Haaland, B., additional, and Qian, P. Z. G., additional
- Published
- 2011
- Full Text
- View/download PDF
27. 1024P - Tumor Vascular Heterogeneity As a Biomarker of Response to Anti-Angiogenic Treatment in Patients with Nasopharyngeal Carcinoma
- Author
-
Teo, Q.Q., Haaland, B., Thng, C.H., Lim, W.T., Koh, T.S., and Ng, Q.
- Published
- 2014
- Full Text
- View/download PDF
28. Low‐value Prostate Cancer Screening: Decision Fatigue in Outpatient Providers' PSA Testing Practices.
- Author
-
Hun, T.C., Ambrose, J.P., Haaland, B., Hanson, H.A., and O'Neil, B.B.
- Subjects
EARLY detection of cancer ,PROSTATE cancer ,WATCHFUL waiting ,FATIGUE (Physiology) - Published
- 2020
- Full Text
- View/download PDF
29. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
- Author
-
Kareff SA, Han S, Haaland B, Jani CJ, Kohli R, Aguiar PN Jr, Huang Y, Soo RA, Rodríguez-Perez Á, García-Foncillas J, Dómine M, and de Lima Lopes G
- Subjects
- Humans, Brazil, Spain, Quality-Adjusted Life Years, Male, Singapore, Female, United States, Middle Aged, Neoplasm Staging, Aged, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological economics, Markov Chains, Cost-Effectiveness Analysis, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung economics, Cost-Benefit Analysis, Lung Neoplasms drug therapy, Lung Neoplasms economics, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal economics
- Abstract
Importance: Standard of care for unresectable locally advanced non-small cell lung cancer (NSCLC) involves definitive chemoradiotherapy followed by maintenance therapy with durvalumab. However, the cost of durvalumab has been cited as a barrier to its use in various health systems., Objective: To evaluate the cost-effectiveness of durvalumab vs placebo as maintenance therapy in patients with unresectable stage III NSCLC from 4 international payer perspectives (US, Brazil, Singapore, and Spain)., Design, Setting, and Participants: In this economic evaluation, a Markov model was designed to compare the lifetime cost-effectiveness of maintenance durvalumab for unresectable stage III NSCLC with that of placebo, using 5-year outcomes data from the PACIFIC randomized placebo-controlled trial. Individual patient data were extracted from the PACIFIC, KEYNOTE-189, ADAURA, ALEX, and REVEL randomized clinical trials to develop a decision-analytic model to determine the cost-effectiveness of durvalumab compared with placebo maintenance therapy over a 10-year time horizon. Direct costs, adverse events, and patient characteristics were based on country-specific payer perspectives and demographic characteristics. The study was conducted from June 1, 2022, through December 27, 2023., Main Outcomes and Measures: Life-years, quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs) were estimated at country-specific willingness-to-pay thresholds ([data reported in US$] US: $150 000 per QALY; Brazil: $22 251 per QALY; Singapore: $55 288 per QALY, and Spain: $107 069 per QALY). One-way and probabilistic sensitivity analyses were performed to account for parameters of uncertainty. A cost-threshold analysis was also performed., Results: The US base-case model found that treatment with durvalumab was associated with an increased cost of $114 394 and improved effectiveness of 0.50 QALYs compared with placebo, leading to an ICER of $228 788 per QALY. Incremental cost-effectiveness ratios, according to base-case models, were $141 146 for Brazil, $153 461 for Singapore, and $125 193 for Spain. Durvalumab price adjustments to the PACIFIC data improved cost-effectiveness in Singapore, with an ICER of $45 164. The model was most sensitive to the utility of durvalumab., Conclusions and Relevance: In this cost-effectiveness analysis of durvalumab as maintenance therapy for unresectable stage III NSCLC, the therapy was found to be cost-prohibitive from the perspective of various international payers according to country-specific willingness-to-pay thresholds per QALY. The findings of the study suggest that discounted durvalumab acquisition costs, as possible in Singapore, might improve cost-effectiveness globally.
- Published
- 2024
- Full Text
- View/download PDF
30. Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients.
- Author
-
Choudry M, Dindinger-Hill K, Ambrose J, Horns J, Vehawn J, Gill H, Murray NZ, Hunt TC, Martin C, Haaland B, Chipman J, Hanson HA, and O'Neil BB
- Subjects
- Humans, Urban Population, Proportional Hazards Models, Utah epidemiology, Rural Population, Neoplasms epidemiology, Urogenital Neoplasms
- Abstract
Introduction: Patients living in rural areas have worse cancer-specific outcomes. This study examines the effect of family-based social capital on genitourinary cancer survival. We hypothesized that rural patients with urban relatives have improved survival relative to rural patients without urban family., Methods: We examined rural and urban based Utah individuals diagnosed with genitourinary cancers between 1968 and 2018. Familial networks were determined using the Utah Population Database. Patients and relatives were classified as rural or urban based on 2010 rural-urban commuting area codes. Overall survival was analyzed using Cox proportional hazards models., Results: We identified 24,746 patients with genitourinary cancer with a median follow-up of 8.72 years. Rural cancer patients without an urban relative had the worst outcomes with cancer-specific survival hazard ratios (HRs) at 5 and 10 years of 1.33 (95% CI 1.10-1.62) and 1.46 (95% CI 1.24-1.73), respectively relative to urban patients. Rural patients with urban first-degree relatives had improved survival with 5- and 10-year survival HRs of 1.21 (95% CI 1.06-1.40) and 1.16 (95% CI 1.03-1.31), respectively., Conclusions: Our findings suggest rural patients who have been diagnosed with a genitourinary cancer have improved survival when having relatives in urban centers relative to rural patients without urban relatives. Further research is needed to better understand the mechanisms through which having an urban family member contributes to improved cancer outcomes for rural patients. Better characterization of this affect may help inform policies to reduce urban-rural cancer disparities., (© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
31. Evaluation of novel candidate filtration markers from a global metabolomic discovery for glomerular filtration rate estimation.
- Author
-
Fino NF, Adingwupu OM, Coresh J, Greene T, Haaland B, Shlipak MG, Costa E Silva VT, Kalil R, Mindikoglu AL, Furth SL, Seegmiller JC, Levey AS, and Inker LA
- Subjects
- Humans, Glomerular Filtration Rate, Creatinine, Biomarkers, Metabolomics, Renal Insufficiency, Chronic
- Abstract
Creatinine and cystatin-C are recommended for estimating glomerular filtration rate (eGFR) but accuracy is suboptimal. Here, using untargeted metabolomics data, we sought to identify candidate filtration markers for a new targeted assay using a novel approach based on their maximal joint association with measured GFR (mGFR) and with flexibility to consider their biological properties. We analyzed metabolites measured in seven diverse studies encompasing 2,851 participants on the Metabolon H4 platform that had Pearson correlations with log mGFR and used a stepwise approach to develop models to < -0.5 estimate mGFR with and without inclusion of creatinine that enabled selection of candidate markers. In total, 456 identified metabolites were present in all studies, and 36 had correlations with mGFR < -0.5. A total of 2,225 models were developed that included these metabolites; all with lower root mean square errors and smaller coefficients for demographic variables compared to estimates using untargeted creatinine. Seventeen metabolites were chosen, including 12 new candidate filtration markers. The selected metabolites had strong associations with mGFR and little dependence on demographic factors. Candidate metabolites were identified with maximal joint association with mGFR and minimal dependence on demographic variables across many varied clinical settings. These metabolites are excreted in urine and represent diverse metabolic pathways and tubular handling. Thus, our data can be used to select metabolites for a multi-analyte eGFR determination assay using mass spectrometry that potentially offers better accuracy and is less prone to non-GFR determinants than the current eGFR biomarkers., (Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
- Author
-
Collier W, Haaland B, Inker LA, Heerspink HJL, and Greene T
- Subjects
- Humans, Bayes Theorem, Biomarkers, Computer Simulation, Clinical Trials as Topic, Renal Insufficiency, Chronic
- Abstract
Background: Surrogate endpoints, such as those of interest in chronic kidney disease (CKD), are often evaluated using Bayesian meta-regression. Trials used for the analysis can evaluate a variety of interventions for different sub-classifications of disease, which can introduce two additional goals in the analysis. The first is to infer the quality of the surrogate within specific trial subgroups defined by disease or intervention classes. The second is to generate more targeted subgroup-specific predictions of treatment effects on the clinical endpoint., Methods: Using real data from a collection of CKD trials and a simulation study, we contrasted surrogate endpoint evaluations under different hierarchical Bayesian approaches. Each approach we considered induces different assumptions regarding the relatedness (exchangeability) of trials within and between subgroups. These include partial-pooling approaches, which allow subgroup-specific meta-regressions and, yet, facilitate data adaptive information sharing across subgroups to potentially improve inferential precision. Because partial-pooling models come with additional parameters relative to a standard approach assuming one meta-regression for the entire set of studies, we performed analyses to understand the impact of the parameterization and priors with the overall goals of comparing precision in estimates of subgroup-specific meta-regression parameters and predictive performance., Results: In the analyses considered, partial-pooling approaches to surrogate endpoint evaluation improved accuracy of estimation of subgroup-specific meta-regression parameters relative to fitting separate models within subgroups. A random rather than fixed effects approach led to reduced bias in estimation of meta-regression parameters and in prediction in subgroups where the surrogate was strong. Finally, we found that subgroup-specific meta-regression posteriors were robust to use of constrained priors under the partial-pooling approach, and that use of constrained priors could facilitate more precise prediction for clinical effects in trials of a subgroup not available for the initial surrogacy evaluation., Conclusion: Partial-pooling modeling strategies should be considered for surrogate endpoint evaluation on collections of heterogeneous studies. Fitting these models comes with additional complexity related to choosing priors. Constrained priors should be considered when using partial-pooling models when the goal is to predict the treatment effect on the clinical endpoint., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
33. Adverse Health Outcomes among Rural and Urban Breast Cancer Survivors: A Population-Based Cohort Study.
- Author
-
Koric A, Mark B, Chang CP, Lloyd S, Dodson M, Deshmukh VG, Newman M, Date A, Gren LH, Porucznik CA, Haaland B, Henry NL, and Hashibe M
- Subjects
- Humans, Female, Cohort Studies, Rural Population, Outcome Assessment, Health Care, Urban Population, Cancer Survivors, Breast Neoplasms epidemiology, Heart Failure
- Abstract
Background: Limited population-based studies have focused on breast cancer survivors in rural populations. We sought to evaluate the risk of adverse health outcomes among rural and urban breast cancer survivors and to evaluate potential predictors for the highest risk outcomes., Methods: A population-based cohort of rural and urban breast cancer survivors diagnosed between 1997 and 2017 was identified in the Utah Cancer Registry (UCR). Rural breast cancer survivors were matched on year (±1 year) and age at cancer diagnosis (±1 year) with up to 5 urban breast cancer survivors (2,359 rural breast cancer survivors; 11,748 urban breast cancer survivors). Cox proportional hazards models were used to calculate HRs with 99% confidence intervals (CI) for adverse health outcomes overall, within 5 years, and >5 years after cancer diagnosis., Results: Compared with urban breast cancer survivors, rural breast cancer survivors had a 39% (HR, 1.39; 95% CI, 1.02-1.65) higher risk of heart failure (HF) within the 5 years of follow-up. Overall, there was no increase in the risk of other evaluated adverse health outcomes. A higher baseline body mass index and Charlson Comorbidity Index, family history of cardiovascular diseases, family history of breast cancer, and advanced cancer stage were risk factors for HF for rural and urban breast cancer survivors, with similar levels of HF risk., Conclusions: Rural residence was associated with an increased risk of HF among breast cancer survivors., Impact: Our study highlights the need for primary preventive strategies for rural cancer survivors at risk of heart failure., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
34. New-Onset Diabetes after an Obesity-Related Cancer Diagnosis and Survival Outcomes in the Women's Health Initiative.
- Author
-
Karra P, Hardikar S, Winn M, Anderson GL, Haaland B, Krick B, Thomson CA, Shadyab A, Luo J, Saquib N, Strickler HD, Chlebowski R, Arthur RS, Summers SA, Holland WL, Jalili T, and Playdon MC
- Subjects
- Female, Humans, Risk Factors, Women's Health, Obesity complications, Obesity epidemiology, Proportional Hazards Models, Diabetes Mellitus epidemiology, Neoplasms diagnosis, Neoplasms epidemiology, Neoplasms complications
- Abstract
Background: Individuals diagnosed with an obesity-related cancer (ORC survivors) are at an elevated risk of incident diabetes compared with cancer-free individuals, but whether this confers survival disadvantage is unknown., Methods: We assessed the rate of incident diabetes in ORC survivors and evaluated the association of incident diabetes with all-cause and cancer-specific mortality among females with ORC in the Women's Health Initiative cohort (N = 14,651). Cox proportional hazards regression models stratified by exposure-risk periods (0-1, >1-3, >3-5, >5-7, and >7-10 years) from ORC diagnosis and time-varying exposure (diabetes) analyses were performed., Results: Among the ORC survivors, a total of 1.3% developed diabetes within ≤1 year of follow-up and 2.5%, 2.3%, 2.3%, and 3.6% at 1-3, 3-5, 5-7, and 7-10 years of follow-up, respectively, after an ORC diagnosis. The median survival for those diagnosed with diabetes within 1-year of cancer diagnosis and those with no diabetes diagnosis in that time frame was 8.8 [95% confidence interval (CI), 7.0-14.5) years and 16.6 (95% CI, 16.1-17.0) years, respectively. New-onset compared with no diabetes as a time-varying exposure was associated with higher risk of all-cause (HR, 1.27; 95% CI, 1.16-1.40) and cancer-specific (HR, 1.17; 95% CI, 0.99-1.38) mortality. When stratified by exposure-risk periods, incident diabetes in ≤1 year of follow-up was associated with higher all-cause (HR, 1.76; 95% CI, 1.40-2.20) and cancer-specific (HR0-1, 1.82; 95% CI, 1.28-2.57) mortality, compared with no diabetes diagnosis., Conclusions: Incident diabetes was associated with worse cancer-specific and all-cause survival, particularly in the year after cancer diagnosis., Impact: These findings draw attention to the importance of diabetes prevention efforts among cancer survivors to improve survival outcomes., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
35. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.
- Author
-
Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN Jr, Thompson IM Jr, and Agarwal N
- Subjects
- Male, Humans, Aged, Androgen Antagonists adverse effects, Prospective Studies, Androgens therapeutic use, Treatment Outcome, Androgen Receptor Antagonists therapeutic use, Castration, Prostatic Neoplasms drug therapy
- Abstract
Importance: Black patients present with more aggressive disease and experience higher mortality than White patients with prostate cancer. Race and social determinants of health influence prostate cancer-specific mortality and overall survival (OS); however, in a previous trial, Black patients did not have inferior outcomes compared with White patients, possibly because of equitable access to care available in a clinical trial setting., Objective: To compare differences in survival outcomes of patients with metastatic castration-sensitive prostate cancer (mCSPC) by race in a phase 3 trial with a large proportion of Black patients., Design, Setting, and Participants: This secondary analysis of patient-level data of a prospective phase 3 randomized clinical trial included patients with newly diagnosed mCSPC enrolled between March 1, 2013, and July 15, 2017. Analysis was conducted between December 2022 and February 2023., Interventions: Patients receiving androgen deprivation therapy were randomized (1:1) to receive either orteronel 300 mg orally twice daily (experimental group) or bicalutamide 50 mg orally daily (control group)., Main Outcomes and Measures: OS, with progression-free survival (PFS) as a secondary end point., Results: Among 1313 participants, 135 (10%) identified as Black and 1077 (82%) as White, with an equal racial distribution between groups. Black patients were younger (median [IQR] age, 65.8 [60-70] vs 68.4 [62.5-74.1] years; P = .001) and had a higher median (IQR) baseline prostate-specific antigen response rate than White patients (54.7 [19.8-222.0] vs 26.7 [9.2-96.0] ng/mL; P < .001). At a median follow-up of 4.9 years, Black and White patients had similar median PFS (2.3 years; 95% CI, 1.8-1.4 years vs 2.9 years; 95% CI, 2.5-3.3 years; P = .71) and OS (5.5 years; 95% CI, 4.8-NR vs 6.3 years; 95% CI, 5.7-NR; P = .65). The multivariable analysis confirmed similar PFS and OS after adjusting for known prognostic factors. No interaction between race and treatment was observed., Conclusions and Relevance: In this secondary analysis of a randomized clinical trial studying androgen deprivation therapy with first- or second-generation androgen receptor pathway inhibitors, both Black and White patients demonstrated similar OS and PFS. Equitable access to care may reduce historical differences in outcomes between Black and White patients with advanced prostate cancer., Trial Registration: ClinicalTrials.gov Identifier: NCT01809691.
- Published
- 2023
- Full Text
- View/download PDF
36. Metabolic obesity phenotypes and obesity-related cancer risk in the National Health and Nutrition Examination Survey.
- Author
-
Winn M, Karra P, Freisling H, Gunter MJ, Haaland B, Litchman ML, Doherty JA, Playdon MC, and Hardikar S
- Subjects
- Humans, Overweight, Nutrition Surveys, Obesity complications, Phenotype, Metabolic Syndrome epidemiology, Metabolic Syndrome etiology, Metabolic Syndrome diagnosis, Neoplasms epidemiology, Neoplasms etiology
- Abstract
Introduction: Body mass index (BMI) fails to identify up to one-third of normal weight individuals with metabolic dysfunction who may be at increased risk of obesity-related cancer (ORC). Metabolic obesity phenotypes, an alternate metric to assess metabolic dysfunction with or without obesity, were evaluated for association with ORC risk., Methods: National Health and Nutrition Examination Survey participants from 1999 to 2018 (N = 19,500) were categorized into phenotypes according to the metabolic syndrome (MetS) criteria and BMI: metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy overweight/obese (MHO) and metabolically unhealthy overweight/obese (MUO). Adjusted multivariable logistic regression models were used to evaluate associations with ORC., Results: With metabolic dysfunction defined as ≥1 MetS criteria, ORC cases (n = 528) had higher proportions of MUNW (28.2% vs. 17.4%) and MUO (62.6% vs. 60.9%) phenotypes than cancer-free individuals (n = 18,972). Compared with MHNW participants, MUNW participants had a 2.2-times higher ORC risk [OR (95%CI) = 2.21 (1.27-3.85)]. MHO and MUO participants demonstrated a 43% and 56% increased ORC risk, respectively, compared to MHNW, but these did not reach statistical significance [OR (95% CI) = 1.43 (0.46-4.42), 1.56 (0.91-2.67), respectively]. Hyperglycaemia, hypertension and central obesity were all independently associated with higher ORC risk compared to MHNW., Conclusions: MUNW participants have a higher risk of ORC than other abnormal phenotypes, compared with MHNW participants. Incorporating metabolic health measures in addition to assessing BMI may improve ORC risk stratification. Further research on the relationship between metabolic dysfunction and ORC is warranted., (© 2023 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
37. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
- Author
-
Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontán F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, and Heerspink HJL
- Subjects
- Humans, Glomerular Filtration Rate, Bayes Theorem, Disease Progression, Biomarkers, Kidney Failure, Chronic, Renal Insufficiency, Chronic
- Abstract
Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. Analyses across a diverse spectrum of interventions and populations is required for acceptance of GFR decline as an endpoint. In an analysis of individual participant data, for each of 66 studies (total of 186,312 participants), we estimated treatment effects on the total GFR slope, computed from baseline to 3 years, and chronic slope, starting at 3 months after randomization, and on the clinical endpoint (doubling of serum creatinine, GFR < 15 ml min
-1 per 1.73 m2 or kidney failure with replacement therapy). We used a Bayesian mixed-effects meta-regression model to relate treatment effects on GFR slope with those on the clinical endpoint across all studies and by disease groups (diabetes, glomerular diseases, CKD or cardiovascular diseases). Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median coefficient of determination (R2 ) = 0.97 (95% Bayesian credible interval (BCI) 0.82-1.00)) and moderately associated with those on chronic slope (R2 = 0.55 (95% BCI 0.25-0.77)). There was no evidence of heterogeneity across disease. Our results support the use of total slope as a primary endpoint for clinical trials of CKD progression., (© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.)- Published
- 2023
- Full Text
- View/download PDF
38. Adipose Tissue Distribution and Body Mass Index (BMI) Correlation With Daily Image-Guided Radiotherapy (IGRT) Shifts of Abdominal Radiation Therapy Patients.
- Author
-
Price RG, Lloyd S, Wang X, Haaland B, Nelson G, and Salter B
- Abstract
Purpose There are several studies suggesting a correlation between image-guided radiotherapy (IGRT) setup errors and body mass index (BMI). However, abdominal fat content has visceral and subcutaneous components, which may affect setup errors differently. This study aims to analyze a potential workflow for characterizing adipose content and distribution in the region of the target that would allow a quickly calculated metric of abdominal fat content to stratify these patients. Methods IGRT shift data was retrospectively tabulated from daily fan-beam CT-on-rails pre-treatment alignment for 50 abdominal radiation therapy (RT) patients, and systematic and random errors in the daily setup were characterized by tabulating average and standard deviations of shift data for each patient and looking at differences for different distributions of adipose content. Visceral and subcutaneous fat content were defined by visceral fat area (VFA) and subcutaneous fat area (SFA) using a region-growing algorithm to contour adipose tissue on CT simulation scans. All contours were created for a single slice at the treatment isocenter, on which the VFA and SFA were calculated. A log-rank test was used to test trends in shifts over quartiles of adiposity. Results VFA ranged from 1.9-342.8c m
2 , and SFA from 11.8-756.0 cm2 . The standard definition (SD) of random error (σ) in the lateral axis for Q1 vs. Q4 VFA was 0.10cm vs. 0.29cm, 0.12cm vs. 0.28cm for SFA, and 0.12cm vs. 0.31cm for BMI. The percentage of longitudinal shifts greater than 10mm for Q1 vs. Q4 VFA was 0% vs. 9%, 2% vs. 19% for SFA, and 0% vs. 20% for BMI. Statistically significant trends in shifts vs. the BMI quartile were seen for both pitch and the longitudinal direction, as well as for pitch corrections vs. the VFA quartile. Conclusion Within this dataset, abdominal cancer patients showed statistically significant trends in shift probability vs. BMI and VFA. Also, patients in the upper quartiles of all adiposity metrics showed an increased SD of σ in the lateral direction and increased shifts over 10 mm in the longitudinal direction. However, despite these relationships, neither VFA nor SFA offered discernible advantages in their relationship to shift uncertainty relative to BMI., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Price et al.)- Published
- 2023
- Full Text
- View/download PDF
39. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD.
- Author
-
Heerspink HJL, Inker LA, Tighiouart H, Collier WH, Haaland B, Luo J, Appel GB, Chan TM, Estacio RO, Fervenza F, Floege J, Imai E, Jafar TH, Lewis JB, Kam-Tao Li P, Locatelli F, Maes BD, Perna A, Perrone RD, Praga M, Schena FP, Wanner C, Xie D, and Greene T
- Subjects
- Humans, Albuminuria diagnosis, Bayes Theorem, Glomerular Filtration Rate, Biomarkers, Creatinine, Renal Insufficiency, Chronic therapy, Renal Insufficiency
- Abstract
Significance Statement: Changes in albuminuria and GFR slope are individually used as surrogate end points in clinical trials of CKD progression, and studies have demonstrated that each is associated with treatment effects on clinical end points. In this study, the authors sought to develop a conceptual framework that combines both surrogate end points to better predict treatment effects on clinical end points in Phase 2 trials. The results demonstrate that information from the combined treatment effects on albuminuria and GFR slope improves the prediction of treatment effects on the clinical end point for Phase 2 trials with sample sizes between 100 and 200 patients and duration of follow-up ranging from 1 to 2 years. These findings may help inform design of clinical trials for interventions aimed at slowing CKD progression., Background: Changes in log urinary albumin-to-creatinine ratio (UACR) and GFR slope are individually used as surrogate end points in clinical trials of CKD progression. Whether combining these surrogate end points might strengthen inferences about clinical benefit is unknown., Methods: Using Bayesian meta-regressions across 41 randomized trials of CKD progression, we characterized the combined relationship between the treatment effects on the clinical end point (sustained doubling of serum creatinine, GFR <15 ml/min per 1.73 m 2 , or kidney failure) and treatment effects on UACR change and chronic GFR slope after 3 months. We applied the results to the design of Phase 2 trials on the basis of UACR change and chronic GFR slope in combination., Results: Treatment effects on the clinical end point were strongly associated with the combination of treatment effects on UACR change and chronic slope. The posterior median meta-regression coefficients for treatment effects were -0.41 (95% Bayesian Credible Interval, -0.64 to -0.17) per 1 ml/min per 1.73 m 2 per year for the treatment effect on GFR slope and -0.06 (95% Bayesian Credible Interval, -0.90 to 0.77) for the treatment effect on UACR change. The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up., Conclusions: In Phase 2 trials of CKD with sample sizes of 100-200 patients per arm and follow-up between 1 and 2 years, combining information from treatment effects on UACR change and GFR slope improved the prediction of treatment effects on clinical end points., (Copyright © 2023 by the American Society of Nephrology.)
- Published
- 2023
- Full Text
- View/download PDF
40. Reliability estimates for assessing meal timing derived from longitudinal repeated 24-hour dietary recalls.
- Author
-
Peterson L, Lee H, Huybrechts I, Biessy C, Neuhouser ML, Haaland B, Krick B, Gunter M, Schulze MB, Jannasch F, Coletta AM, Hardikar S, Chaix A, Bauer CX, Xiao Q, and Playdon MC
- Subjects
- Humans, Prospective Studies, Reproducibility of Results, Meals, Diet, Energy Intake physiology
- Abstract
Background: Regulating meal timing may have efficacy for improving metabolic health for preventing or managing chronic disease. However, the reliability of measuring meal timing with commonly used dietary assessment tools needs characterization prior to investigating meal timing and health outcomes in epidemiologic studies., Objectives: To evaluate the reliability of estimating meal timing parameters, including overnight fasting duration, the midpoint of overnight fasting time, the number of daily eating episodes, the period with the largest percentage of daily caloric intake, and late last eating episode (> 09:00 pm) from repeated 24-h dietary recalls (24HRs)., Methods: Intraclass correlation coefficients (ICC), Light's Kappa estimates, and 95% CIs were calculated from repeated 24HR administered in 3 epidemiologic studies: The United States-based Interactive Diet and Activity Tracking in AARP (IDATA) study (n = 996, 6 24HR collected over 12-mo), German EPIC-Potsdam Validation Study (European Prospective Investigation into Cancer and Nutrition Potsdam Germany cohort) (n = 134, 12 24HR collected over 12-mo) and EPIC-Potsdam BMBF-II Study (Federal Ministry of Education and Research, "Bundesministerium für Bildung und Forschung") (n = 725, 4 24HR collected over 36 mo)., Results: Measurement reliability of overnight fasting duration based on a single 24HR was "poor" in all studies [ICC range: 0.27; 95% CI: 0.23, 0.32 - 0.46; 95% CI: 0.43, 0.50]. Reliability was "moderate" with 3 24HR (ICC range: 0.53; 95% CI: 0.47, 0.58 in IDATA, 0.62; 95% CI: 0.52, 0.69 in the EPIC-Potsdam Validation Study, and 0.72; 95% CI: 0.70-0.75 in the EPIC-Potsdam BMBF-II Study). Results were similar for the midpoint of overnight fasting time and the number of eating episodes. Reliability of measuring late eating was "fair" in IDATA (Light's Kappa: 0.30; 95% CI: 0.21, 0.39) and "slight" in the EPIC-Potsdam Validation study and the EPIC-Potsdam BMBF-II study (Light's Kappa: 0.19; 95% CI: 0.15, 0.25 and 0.09; 95% CI: 0.06, 0.12, respectively). Reliability estimates differed by sex, BMI, weekday, and season of 24HR administration in some studies., Conclusions: Our results show that ≥ 3 24HR over a 1-3-y period are required for reliable estimates of meal timing variables., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
41. Objectively-Assessed Ultraviolet Radiation Exposure and Sunburn Occurrence.
- Author
-
Stump TK, Fastner S, Jo Y, Chipman J, Haaland B, Nagelhout ES, Wankier AP, Lensink R, Zhu A, Parsons B, Grossman D, and Wu YP
- Subjects
- Humans, Ultraviolet Rays adverse effects, Forecasting, Risk Factors, Sunburn epidemiology, Sunburn etiology, Melanoma epidemiology
- Abstract
Ultraviolet radiation (UVR) exposure is the primary modifiable risk factor for melanoma. Wearable UVR sensors provide a means of quantifying UVR exposure objectively and with a lower burden than self-report measures used in most research. The purpose of this study was to evaluate the relationship between detected UVR exposure and reported sunburn occurrence. In this study, a UVR monitoring device was worn by 97 parent-child dyads during waking hours for 14 days to measure instantaneous and accumulated UVR exposure. The results showed that the participants' total UVR exposure was associated with reported sunburn after adjusting for Fitzpatrick skin type and geographic location. It was observed that one standard erythemal dose (SED) increase in the participants' daily total UVR exposure was associated with reported sunburn (an odds ratio (OR) of 1.26 with a 95% CI of 1.13 and 1.41, and p < 0.001 for parents and an OR of 1.28 with a 95% CI of 1.12 and 1.47, and p < 0.001 for children). A one-SED increase in the participants' UVR exposure from 10 am to 4 pm was also associated with reported sunburn (an OR of 1.31 with a 95% CI of 1.15 and 1.49, and p < 0.001 for parents and an OR of 1.33 with a 95% CI of 1.12 and 1.59, and p = 0.001 for children). We found that elevated UVR exposure recordings measured by the UVR sensor were associated with reported sunburn occurrence. Future directions for wearable UVR sensors may include their use as an intervention tool to support in-the-moment sunburn prevention.
- Published
- 2023
- Full Text
- View/download PDF
42. Cluster analysis to identify patient profiles and substance use patterns among pregnant persons with opioid use disorder.
- Author
-
Charron E, Yu Z, Lundahl B, Silipigni J, Okifuji A, Gordon AJ, Baylis JD, White A, Carlston K, Abdullah W, Haaland B, Krans EE, Smid MC, and Cochran G
- Abstract
The study objective was to identify distinct profiles of pregnant persons with opioid use disorder (PP-OUD) using cluster analysis and examine difference in substance use patterns between profiles. We examined data from 104 PP-OUD ≤ 32 weeks of gestation who were recruited into a behavioral health clinical trial at two academic medical centers. We used Partitioning Around Medoids analysis to identify clusters and explored patterns of substance use and substance use treatment between clusters using bivariate statistical tests and regression methods. We identified two distinct clusters of participants, including 'Group A' (n = 68; 65.4 %) and 'Group B' (n = 36; 34.6 %). Group A had fewer members who were not employed (38 % vs 58 %) and incarcerated (3 % vs 8 %) compared to Group B. Group A compared with Group B included more members with: a history of overdose (72 % vs 50 %); anxiety (85 % vs 25 %); ≥moderate pain (76 % vs 22 %); ≥moderate depression (75 % vs 36 %); ≥moderate drug use severity (94 % vs 78 %); and, more days of cannabis (mean: 6.2 vs 2.3 days), stimulant (mean: 4.5 vs 1.3 days), and injection heroin (mean: 1.3 vs 0 days) use in the past 30 days ( P < 0.05 for all comparisons). Clusters of PP-OUD differed with respect to sociodemographic characteristics, mental health conditions, and substance use patterns. More research is needed to confirm identified profiles and assess treatment outcomes associated with cluster membership., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
43. Association of Telomere Length with Colorectal Cancer Risk and Prognosis: A Systematic Review and Meta-Analysis.
- Author
-
Pauleck S, Sinnott JA, Zheng YL, Gadalla SM, Viskochil R, Haaland B, Cawthon RM, Hoffmeister A, and Hardikar S
- Abstract
(1) Background: Colorectal cancer risk and survival have previously been associated with telomere length in peripheral blood leukocytes and tumor tissue. A systematic review and meta-analysis of the literature was conducted. The PubMed, Embase, and Web of Science databases were searched through March 2022. (2) Methods: Relevant studies were identified through database searching following PRISMA guidelines. Risk estimates were extracted from identified studies; meta-analyses were conducted using random effects models. (3) Results: Fourteen studies were identified (eight on risk; six on survival) through systematic review. While no association was observed between circulating leukocyte telomere length and the risk of colorectal cancer [overall OR (95% CI) = 1.01 (0.82-1.24)], a worse survival for those with shorter telomeres in leukocytes and longer telomeres in tumor tissues was observed [Quartile
1 /Quartile2-4 overall HR (95% CI) = 1.41 (0.26-7.59) and 0.82 (0.69-0.98), respectively]. (4) Conclusions: Although there was no association with colorectal cancer risk, a poorer survival was observed among those with shorter leukocyte telomere length. Future larger studies evaluating a potentially non-linear relationship between telomeres and colorectal cancer are needed.- Published
- 2023
- Full Text
- View/download PDF
44. Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.
- Author
-
Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, and Greene T
- Subjects
- Humans, Glomerular Filtration Rate, Biomarkers, Disease Progression, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic therapy, Renal Insufficiency, Chronic epidemiology, Kidney Failure, Chronic, Renal Insufficiency
- Abstract
Background: The GFR slope has been evaluated as a surrogate end point for kidney failure in meta-analyses on a broad collection of randomized controlled trials (RCTs) in CKD. These analyses evaluate how accurately a treatment effect on GFR slope predicts a treatment effect on kidney failure. We sought to determine whether severity of CKD in the patient population modifies the performance of GFR slope., Methods: We performed Bayesian meta-regression analyses on 66 CKD RCTs to evaluate associations between effects on GFR slope (the chronic slope and the total slope over 3 years, expressed as mean differences in ml/min per 1.73 m2/yr) and those of the clinical end point (doubling of serum creatinine, GFR <15 ml/min per 1.73 m2, or kidney failure, expressed as a log-hazard ratio), where models allow interaction with variables defining disease severity. We evaluated three measures (baseline GFR in 10 ml/min per 1.73 m2, baseline urine albumin-to-creatinine ratio [UACR] per doubling in mg/g, and CKD progression rate defined as the control arm chronic slope, in ml/min per 1.73 m2/yr) and defined strong evidence for modification when 95% posterior credible intervals for interaction terms excluded zero., Results: There was no evidence for modification by disease severity when evaluating 3-year total slope (95% credible intervals for the interaction slope: baseline GFR [-0.05 to 0.03]; baseline UACR [-0.02 to 0.04]; CKD progression rate [-0.07 to 0.02]). There was strong evidence for modification in evaluations of chronic slope (95% credible intervals: baseline GFR [0.02 to 0.11]; baseline UACR [-0.11 to -0.02]; CKD progression rate [0.01 to 0.15])., Conclusions: These analyses indicate consistency of the performance of total slope over 3 years, which provides further evidence for its validity as a surrogate end point in RCTs representing varied CKD populations., (Copyright © 2023 by the American Society of Nephrology.)
- Published
- 2023
- Full Text
- View/download PDF
45. Impact of academic medical center access on outcomes in multiple myeloma.
- Author
-
Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, and Sborov DW
- Subjects
- United States epidemiology, Humans, Retrospective Studies, Medicaid, Academic Medical Centers, Survival Analysis, Multiple Myeloma therapy
- Abstract
Treatment at academic cancer centers (ACs) is associated with improved survival across hematologic malignancies, though the benefit in multiple myeloma (MM) has not been examined. This study aims to evaluate survival outcomes at Commission on Cancer accredited ACs compared to non-academic centers (NACs) for patients receiving MM-directed therapy. The National Cancer Database (NCDB) was used to identify demographics and overall survival (OS) of MM patients diagnosed from 2004 to 2017 and to compare outcomes by facility type. Survival analysis was repeated in a propensity score matched cohort, with NACs matched 1:1 to ACs by age, race, comorbidity score, insurance, year of diagnosis, distance traveled, and income. Of 163 375 MM patients, 44.5% were treated at ACs. Patients at ACs were more likely to receive MM-directed therapy compared to NACs (81% vs. 73%, p < .001). For patients receiving treatment, median OS at ACs was 71.3 months versus 41.2 months at NACs (p < .001). When adjusted for baseline demographics, patients treated at ACs had reduced mortality; hazard ratio (HR) 0.79 (95% CI 0.78-0.81, p < .001). The propensity score matched cohort maintained this survival benefit with a median OS of 59.9 months at ACs versus 37.0 months at NACs (p < .001), HR of 0.66 (95% CI 0.64-0.67, p < .001). ACs treated younger patients with fewer comorbidities and were more likely to treat racial minorities and patients with Medicaid or private insurance, and the uninsured. In this analysis, MM patients treated at ACs have significantly improved survival. While potentially related to access to specialized care, socioeconomic factors that drive facility selection may also contribute., (© 2022 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
46. Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
- Author
-
Sama S, Kerrigan K, Sinnott JA, Puri S, Akerley W, Haaland B, and Patel S
- Subjects
- Aged, Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin therapeutic use, Cisplatin therapeutic use, Platinum therapeutic use, Treatment Outcome, Lung Neoplasms, Small Cell Lung Carcinoma drug therapy
- Abstract
Introduction: Limited-stage small-cell lung cancer (LS-SCLC) is potentially curable with concurrent chemoradiation (CRT). Cisplatin is the preferred platinum for the chemotherapy backbone in national guidelines. Unfortunately, many LS-SCLC patients are elderly, with comorbidities and poor performance status (PS), which preclude the use of cisplatin. Carboplatin may be a suitable alternative. This analysis evaluates the overall survival (OS) and time to next treatment (TTNT) in LS-SCLC patients receiving concurrent CRT by platinum use., Materials and Methods: The study included LS-SCLC patients in the Flatiron Health nationwide de-identified electronic health record-derived database who received CRT in 2013-2019 with follow-up through May 2020. TTNT and OS were compared using both unadjusted and inverse propensity-weighted Cox proportional hazards models., Results: This study included patients treated with carboplatin (n = 600) or cisplatin (n = 572) in combination with etoposide and radiation. Cisplatin patients were younger, had a shorter time from diagnosis to radiation, and had less kidney disease. In an unadjusted analysis, median overall survival (mOS) was greater in the cisplatin group than the carboplatin group with mOS of 22.3 months vs. 19.2 months and Hazard Ratio (HR) of 0.83 (p = 0.01). In the inverse propensity-weighted analysis, this difference was no longer significant (HR 0.93, p = 0.37). No differences were seen in TTNT., Conclusion: When balancing on key clinical factors, we observed no statistical difference in OS or TTNT by platinum choice in real-world LS-SCLC patients treated with CRT. Although observational, the results from this large data set are consistent with the hypothesis that either cisplatin or carboplatin is an appropriate therapy regardless of health status., Competing Interests: Declaration of Competing Interest Dr. Haaland served as a consultant for Guidepoint Global, Value Analytics Labs, National Kidney Foundation, and Proxima Clinical Research. Dr. Puri reports receiving consulting/advisory fees from AstraZeneca, G1 therapeutics and Jazz Pharma and also reports travel funding from Dava Oncology. Dr. Patel reports receiving institutional funding from Takeda, Merck, AstraZeneca, Janssen; and consulting fees/advisory board fees from AstraZeneca, Natera, Boehringer Ingelheim, Blueprint Medicines, TerSera Therapeutics, Takeda, Regeneron, and Sanofi. Dr. Akerley reports participation on data safety/ advisory board for Lilly. Jennifer Sinnott reports an NIH funding grant. The remaining authors declare no conflict of interest., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
47. Metabolic dysfunction and obesity-related cancer: Results from the cross-sectional National Health and Nutrition Examination Survey.
- Author
-
Winn M, Karra P, Haaland B, Doherty JA, Summers SA, Litchman ML, Gunter MJ, Playdon MC, and Hardikar S
- Subjects
- Young Adult, Humans, Nutrition Surveys, Cross-Sectional Studies, Obesity complications, Obesity epidemiology, Risk Factors, Metabolic Syndrome epidemiology, Neoplasms etiology, Neoplasms complications
- Abstract
Background: Metabolic syndrome (MetS), a group of risk factors that define metabolic dysfunction in adults, is strongly associated with obesity and is an emerging risk factor for cancer. However, the association of MetS and degree of metabolic dysfunction with obesity-related cancer is unknown., Methods: Using National Health and Nutrition Examination Survey data from 1999 to 2018, we identified 528 obesity-related cancer cases and 18,972 cancer-free participants. MetS was defined as the presence of or treatment for ≥3 of hyperglycemia, hypertension, hypertriglyceridemia, low HDL-cholesterol, and abdominal obesity. A metabolic syndrome score (MSS) was computed as the total number of abnormal MetS parameters to determine the severity of metabolic dysfunction. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression models, adjusting for sociodemographic and lifestyle factors., Results: About 45.7% of obesity-related cancer cases were classified as having MetS compared with only 33.0% of cancer-free participants. Overall, MetS and MSS were not associated with obesity-related cancer. However, MSS was associated with higher obesity-related cancer risk among participants under 50 years of age (OR [95% CI] = 1.28 [1.08-1.52]). When evaluating MSS categorically, compared with healthy participants with no abnormal MetS parameters (MSS = 0), participants with one or two abnormal parameters had a statistically significant higher risk of obesity-related cancer (OR [95% CI] = 1.73 [1.06-2.83])., Conclusions: Metabolic dysfunction is associated with a higher risk of obesity-related cancer, particularly in young adults under 50 years of age, and among participants with one or two abnormal metabolic parameters. A more accurate indicator of metabolic dysfunction, beyond metabolic syndrome, is needed to better assist in stratifying individuals for obesity-related cancer risk., (© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
48. Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy.
- Author
-
Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, and Sborov D
- Subjects
- Humans, Prognosis, ADP-ribosyl Cyclase 1, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy, Neoplasms, Plasma Cell
- Published
- 2022
- Full Text
- View/download PDF
49. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer.
- Author
-
Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, and Agarwal N
- Subjects
- Male, Humans, Androgen Antagonists therapeutic use, Biomarkers, Tumor, Prognosis, Castration, Neoplastic Cells, Circulating pathology, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant drug therapy
- Abstract
Approximately 20% of men with metastatic castration-sensitive prostate cancer (mCSPC) progress within 1 year of treatment, and biomarkers to identify them up front are lacking. In a randomized phase III trial in men with mCSPC (SWOG S1216), higher baseline circulating tumor cells (CTCs) were prognostic of inferior outcomes. We aimed to validate these findings and interrogate corresponding tumor genomic profiles. Consecutively seen men with newly diagnosed mCSPC undergoing systemic therapy and baseline CTC enumeration by CellSearch assay were included. Gene alterations were determined by comprehensive genomic profiling of tumor tissue by Clinical Laboratory Improvement Amendments-certified lab. The relationship between categorized CTC counts and both progression-free survival (PFS) and overall survival (OS) was assessed in the context of Cox proportional hazards models, both unadjusted and adjusted for age, Gleason score, PSA at androgen-deprivation therapy initiation, disease volume, de novo status, treatment intensification, and number of altered genes. Overall, 103 patients were included in the analysis. On multivariate analysis high CTCs (≥ 5 vs. 0) were associated with poorer PFS [HR, 4.52; 95% confidence interval (CI), 1.84-11.11; P = 0.001) and OS (HR, 3.59; 95% CI, 0.95-13.57; P = 0.060). Patients with higher CTC counts had a greater number of altered genes and total number of alterations (all P < 0.02). In this article, for the first time, we externally validate the association of higher CTC counts with inferior survival outcomes in men with mCSPC and show a distinct associated tumor genomic landscape. These findings may improve prognostication, patient counseling, and treatment selection in men with mCSPC., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
50. Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study.
- Author
-
Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, and Garrido-Laguna I
- Subjects
- Humans, Neoplasm Recurrence, Local pathology, Prognosis, Retrospective Studies, Treatment Outcome, Adenocarcinoma surgery, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal surgery, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms surgery
- Abstract
Background: A majority of patients undergoing curative intent surgery for pancreatic ductal adenocarcinoma (PDAC) will unfortunately develop recurrent disease. Treatment outcomes for patients with metastatic disease remain suboptimal. In this study, we evaluated clinical outcomes of patients with recurrent PDAC who received systemic therapy and compared outcomes to patients with de novo metastatic PDAC undergoing systemic therapy., Methods: Patients diagnosed with metastatic PDAC between 2014 and 2019 were included using a real-world database. Patients were characterized as either de novo or recurrent based on the date of metastatic diagnosis and history of surgical resection. Overall survival (OS) was summarized within groups via Kaplan-Meier survival estimates and compared using Cox proportional hazards models., Results: We included 5170 patients with metastatic PDAC, of which 1101 (21.3%) were classified as having recurrent disease. Median OS for the recurrent group was significantly greater at 10.8 m (95% CI 9.9-11.7) than in the de novo group at 7.3 m (95% CI 7.0-7.7, p < 0.001). We did not observe a significant difference in OS based on when patients recurred after surgery: 10.0 m (95% CI 8.7-11) within six months of surgery versus 11.6 m (95% CI 10-12, p = 0.256) greater than six months from surgery., Conclusions: These data support the inclusion of patients with recurrent PDAC in clinical trials for advanced disease, including those who develop recurrent disease within six months of surgery. Due to observed differences in survival, randomization should be stratified by disease presentation (recurrent vs de novo)., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.